Trials / Completed
CompletedNCT05320575
Zanubrutinib for HLH
Zanubrutinib Monotherapy in Patients With Hemophagocytic Lymphohistiocytosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective single-arm clinical study, focusing on Hemophagocytic lymphohistocytosis，to evaluate the clinical efficacy and safety of zanubrutinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment. |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2022-04-11
- Last updated
- 2024-04-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05320575. Inclusion in this directory is not an endorsement.